JUNS - Jupiter Neurosciences Market Capitalization-to-Revenue Ratio
Jupiter Neurosciences Inc faces logistical risks and patent protection complexities driven by geopolitics. However, a unique method of delivering substances to the brain ensures high business scalability. The current success of management depends directly on clinical test results. The price-to-sales ratio reflects market expectations, with the parameter reaching 41.20, which determines the asset's current valuation.
Metric breakdowns and analytics for Jupiter Neurosciences Inc (JUNS)
- share price and consensus valuation forecast:
- market capitalization statistics:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Jupiter Neurosciences Inc|JUNS - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital jupiterneurosciences.com|JUNS - Company Debts|Debts to Book Value Jupiter Neurosciences|JUNS - Company Long-Term Debt|Short-Term Debt Volume Jupiter Neurosciences|Quick Liquidity Indicator jupiterneurosciences.com
- net income and valuation multiples indicators:
JUNS - Net Profit|Company Profit Forecast Jupiter Neurosciences Inc|JUNS - P/E Multiple|Projected Price to Earnings Ratio Jupiter Neurosciences, Inc.|JUNS - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Jupiter Neurosciences|JUNS - Operating profit EBITDA|Net earnings per share for the last 12 months Jupiter Neurosciences|JUNS - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months jupiterneurosciences.com|JUNS - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Jupiter Neurosciences Inc
- issuer revenue and sales details:
Fundamental company analysis:JUNS - Jupiter Neurosciences, Inc.
The stability of raw material supplies for neurotherapy at Jupiter Neurosciences Inc. (JUNS) establishes a foundation for assessing the business's real value by comparing market demand with revenue volumes. The price-to-sales ratio, reflected in the P/S valuation, allows investors to filter out speculative noise from fundamental growth. This metric measures how much investors are willing to pay per unit of generated revenue. Analyzing the curve helps balance potential profits against the risk of a prolonged drawdown.
Competitors of Jupiter Neurosciences Inc
BIIB (biogen.com) - Market Capitalization-to-Revenue Ratio|Neurocrine Biosciences, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio RGC|AXSM - Price-to-Revenue Ratio|ACAD (ACADIA Corp) - Market Cap to Revenue Ratio|XENE: P/S Multiple|Price to Sales vikingtherapeutics.com (VKTX)|Market Cap to Revenue SUPN|P/S Multiple Catalyst Pharma|Price-to-Revenue Ratio Denali Therapeutics Inc (DNLI)|HRMY (Harmony Corp) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Biohaven Ltd. BHVN|amylyx.com (AMLX) - Price to Sales|TRVI - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Praxis Precision Medicines Inc PRAX|AVXL: P/S Multiple|Market Cap to Revenue CeriBell EEG|PRTA (Prothena Biosciences) - P/S Multiple|Alector Therapeutics (ALEC) - Price-to-Revenue Coefficient|P/S Multiple ANNX|OMER - Price to Sales|Price-to-Revenue Ratio Neurogene Corp NGNE|ACIU: Market Cap to Revenue Ratio|Voyager Therapeutics - P/S Multiple|neumoratx.com (NMRA) - Market Cap to Revenue|SCLX: P/S Multiple|Price to Sales Tevogen Bio Holdings Inc. (TVGN)|Price-to-Revenue Ratio Alpha Cognition Inc|Cognition Therapeutics Inc. (CGTX) - Price-to-Revenue Coefficient|Market Cap to Revenue IKT (Inhibikase Therapeutics)|SAVA (cassavasciences.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ASRT (Assertio)|Price-to-Revenue Coefficient Coya Therapeutics Inc (COYA)|VTGN - Price-to-Revenue Ratio|OVID (Ovid Therapeutics Inc.) - Market Cap to Revenue Ratio|ABOS: P/S Multiple|Market Cap to Revenue cervomed.com|Price-to-Revenue Ratio Alterity Therapeutics Ltd.|CLNN (Clene Nanomedicine) - Market Cap to Sales Volume|Market Cap to Revenue PEPG (PepGen Inc.)|P/S Multiple Relmada Corp (RLMD)|Price-to-Revenue Ratio Annovis Bio, Inc. ANVS|GRCE: Market Cap to Revenue Ratio|AIFF - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Klotho Neurosciences Inc KLTO|neurosense-tx.com (NRSN) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio RVPH|MTVA (MetaVia Inc.) - P/S Multiple|Price to Sales neuraxis.com NRXS|Market Cap to Revenue HSDT (Helius Medical)|P/S Multiple passagebio.com (PASG)|Price-to-Revenue Ratio Neuphoria Therapeutics NEUP|Market Capitalization-to-Revenue Ratio NERV|ATHA - Price-to-Revenue Ratio|Price to Sales addextherapeutics.com|alzamend.com (ALZN) - Price-to-Revenue Ratio|CYCN: Market Cap to Sales Volume|Market Cap to Revenue PTIX|P/S Multiple Pasithea|Price-to-Revenue Ratio Cortigent, Inc. (CRGT)|ATXI: Price-to-Sales Ratio|P/S Multiple BCLI (BrainStorm Cell Therapeutics)|Price-to-Revenue Coefficient Cara Therapeutics Inc. (CARA)|CHRO: Market Cap to Revenue|Eliem Therapeutics - Market Cap to Sales Volume|ITCI: P/S Multiple|Price to Sales longboardpharma.com (LBPH)|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGN: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue NRBO (NeuroBo)|SAGE (Sage Therapeutics Inc) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Synaptogenix, Inc. SNPX|TRVN: Market Cap to Revenue Ratio|Vigil Neuro - P/S Multiple|Price to Sales anewmeds.com|CERE (Cerevel) - Market Cap to Revenue
